“Meeting the Challenge of Manufacturing Advanced Therapies: Cell Therapies, Gene-mediated Cell Therapies, and Viral Vectors”

PHILADELPHIA, PA (May 31, 2019) – WuXi Advanced Therapies (ATU), a Contract Development and Manufacturing (CDMO) organization dedicated to accelerating and transforming development and manufacturing of cell and gene, is pleased to announce that Felix Hsu, M.B.A, Senior Vice President and Global Head of WuXi Advanced Therapies will be speaking during the 17th Annual Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) conference this Friday, May 31, 2019.

SAPA-GP is a professional organization founded in 2002 to serve the rapidly growing pharmaceutical professional community in the Greater Philadelphia area which is a major hub for global pharmaceutical companies, biotech companies, and academic institutions. At 9 a.m. Mr. Hsu will be presenting ‘Meeting the Challenge of Manufacturing Advanced Therapies: Cell Therapies, Gene-mediated Cell Therapies, and Viral Vectors’ during SAPA-GP’s Plenary Session: Changing Dynamics of Global Life Science.

Mr. Hsu has nearly 31 years of experience in life sciences industry and serves as an Advisory Board Member on Jefferson Institute for Bioprocessing. He has mainly held executive and senior positions at the following companies: WuXi AppTec, Medtronic and Abbott Laboratories. He has studied at the University of Michigan – Stephen M. Ross School of Business where he received a Master’s degree in Business Administration and Management.

Click here for more information about the SAPA-GP Conference 




WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. The advanced therapies business unit of WuXi AppTec is a Contract Development and Manufacturing Organization (CDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability.

Please visit http://www.wuxiapptec.com and www.advancedtherapies.com.


Media Contact:


WuXi Advanced Therapies

Min Park

Sr. Director, Marketing



Learn more about our integrated CDMO and Testing Services.

Speak with our experts